Sanofi and Regeneron’s dupilumab approved by FDA for urticaria
Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU)
Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU)
What's Your Reaction?
